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REVIEW OF PATIENT-REPORTED OUTCOME MEASURES FOR DAYTIME 
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OBJECTIVES: ‘Daytime functioning’ is a widely used outcome to describe quality of 
patients’ functional performance during daytime and gaining popularity as an efﬁcacy 
outcome in pharmaceutical interventions. The purpose of this study was to conduct 
a review of the literature and identify studies and patient-reported outcome instru-
ments that purport to measure daytime functioning. METHODS: A search was con-
ducted of the English-language studies published between January 1950 and June 2008 
using Medline. Key terms used were ‘daytime function and questionnaires’, ‘daytime 
functioning and quality of life’, ‘daytime functioning and questionnaires’, and ‘daytime 
functioning and quality of life’. Studies that observed functional performance from 
adult population were exclusively selected and of those articles, patient-reported 
questionnaires were identiﬁed. Validity of instruments was assessed based on reported 
psychometric properties. RESULTS: Total of 55 articles were identiﬁed. Studied 
patient population had sleep disorders (including apnea) (n  47), cancer (n  2), 
restless leg syndrome (n  2), allergic rhinitis (n  1), Alzheimer’s disease (n  1), coro-
nary artery disease (n  1), overactive bladder (n  1), and Parkinson’s disease (n  
1). Of these, 45% (n  25) articles included a patient-reported outcome questionnaire 
that claimed to measure daytime functioning. The remaining articles (55% n  30) 
included objective measurement to describe daytime function performance or used 
questionnaires without the supporting evidence of reliability, validity and interpret-
ability. After excluding duplicated PRO-questionnaires, 13 tools were identiﬁed and 
changes in patients’ functioning were observed from different areas; generic disease 
state (i.e. health, social support and activities survey) (n  4), sleep disorders (n  4), 
psychiatry (n  3) and fatigue (n  1). CONCLUSIONS: Not all studies that purport 
to measure daytime functioning used validated PRO tools to measure changes in 
daytime functioning. The criteria of deﬁning daytime functioning were differed among 
different disease states. Future studies that will investigate the domain of daytime 
functioning, it is recommended to select appropriate validated PRO instruments that 
can support the intended claim.
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OBJECTIVES: To evaluate the factors driving selection of the primary medication for 
multiple sclerosis (MS) by patients. METHODS: Baseline data from ROBUST, which 
is a 12-month, US prospective, observational, open-label, single-arm, multi-center 
outcomes study of Interferon B-1b given every other day for relapsing forms of 
MSwere analyzed. At baseline, patients were asked to rate the importance of factors 
that are typically considered before making a decision to select the primary medication 
to treat MS (on a scale of 1  not at all important through 5  very important). Twelve 
factors were evaluated: how well medication works, how much medication is given 
per dose, convenience of taking medication, convenience of storing medication, fre-
quency of administration, information in product decision kit, injection needle of the 
medication, personal research, doctor recommendation, family opinion, opinion of 
other MS patients and recommendation of MS advocacy groups. Mean scores on each 
factor were compared across patient sociodemographic characteristics, primary medi-
cation types and disease severity. RESULTS: At baseline, a total of 99 reported taking 
medication to treat their MS and thus provided responses on the items of interest. In 
this sample, 80.8% were females, 61.6% married, 70.4% below 50 years old and 
82.8% White. Among all patients, the highest importance scores were received for 
how well the medications controls MS progression (Mean [95% Conﬁdence Interval] 
 4.72 [4.57–4.86]) followed by their doctor’s recommendation (4.57 [4.41–4.72]), 
the convenience of taking the medications (3.88 [3.63–4.13]), personal research (3.81 
[3.56–4.05]) and the convenience of storing the medication (3.71 [3.44–3.98]). 
These factors and their order of importance remained consistent across patient 
sociodemographic characteristics, primary medication types and disease severity. 
CONCLUSIONS: Contributing to the limited published research about factors 
 considered by patients when selecting primary medication for their MS, this analysis 
found that medication effectiveness to control MS progression and doctor 
recommendation are the most important drivers of medication selection.
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OBJECTIVES: To explore the association of baseline health-related quality of life 
(HRQoL) and clinical measures of disability and motor functioning in a real-world 
observational study of multiple sclerosis (MS) patients. METHODS: The Real-World 
Betaseron® Outcomes Study (ROBUST) is a US, prospective, 12-month, observational, 
single-arm, open-label, multi-center outcomes study of interferon beta-1b given every 
other day for MS. A total of 226 patients were registered at 52 neurologists’ sites. 
Clinical measures and patient outcomes were reported by physicians and patients via 
a web-based data capture tool. The Kurtzke Expanded Disability Status Scale (EDSS) 
and Timed 25-foot Walk (T25FW; in seconds) were measured by the neurologist at 
baseline to evaluate patient disability and motor functioning. HRQoL was measured 
at baseline for 191 patients via the SF-12 Health Survey. For this analysis, EDSS and 
T25FW were categorized into ﬁve (0, 1–2, 2.5–4, 4.5–5.5, 6) and two (  7, 7 sec) 
groups, respectively. SF-12 results were summarized by Physical Component Score 
(PCS-12) and Mental Component Score (MCS-12). Analysis of variance methods were 
used to explore the association of baseline HRQoL and clinically measured EDSS and 
T25FW. RESULTS: At higher EDSS scores (i.e., worsening disability), both physical 
and mental HRQoL were lower; however, this association was only statistically sig-
niﬁcant for PCS-12 (p   .001 for PCS-12, p  0.707 for MCS-12). For PCS-12, 
among adjacent EDSS groups, pairwise differences were statistically signiﬁcant between 
EDSS  1–2 vs. EDSS  2.5–4 (44.0 vs. 37.2; p  .0004), suggesting a marked worsen-
ing of physical HRQoL at or above the disability threshold of EDSS  2.5. Both PCS-12 
and MCS-12 were higher for the group with better ambulation: T25FW   7 sec vs. 
T25FW 7 sec (43.5 vs. 37.0, p  0.001 for PCS-12; 43.9 vs. 41.0, p  0.079 for 
MCS-12). CONCLUSIONS: Physical HRQoL is associated with functional impair-
ment assessed via the EDSS and T25FW. This suggests that the PCS-12 component 
of the generic HRQoL tool reﬂects clinical functional impairment in MS patients.
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LARGE MULTINATIONAL OBSERVATION STUDY
Günther OH1, Miltenburger C2, Pozzilli C3, Oentrich W4
1i3 Innovus Berlin, Berlin, Germany, 2i3 Innovus, Berlin, Germany, 3University of Rome La 
Sapienza, Rome, Italy, 4Bayer Schering Pharma AG, Berlin, Germany
OBJECTIVES: Health related quality of life (HrQoL) is an important outcome in 
multiple sclerosis (MS). As part of the measurement system “Functional Assesment of 
Chronic Illness Therapy (FACIT)” targeted to the management of chronic illnesses, 
the Functional Assessment of MS (FAMS) is a self-reported questionnaire assessing 
patient-reported treatment effects in MS studies. Although the FAMS is validated in 
MS, the link between meaningful clinical efﬁcacy and FAMS score changes remains 
unclear. Objective was to determine anchor-based “clinical important differences” 
(CID) in FAMS total score (FAMS TS) and FAMS trial outcome index (FAMS TOI) 
using disability as measured by the Expanded Disability Status Scale (EDSS). 
METHODS: 6 months data from a prospective, observation study (BetaPlus) in 
patients with relapsing MS were used. All patients had been switched from another 
drug to interferon beta-1b 1–3 months before inclusion. The EDSS, the FAMS-TS, the 
FAMS-TOI were assessed at baseline and 6 months, with 1078 respondents at baseline 
and 950 at follow-up. Regression analysis was used to estimate CID of FAMS change 
scores by three anchor categories of EDSS change (“deteriorated”, “unchanged”, 
“improved”). Distribution based measures (standardized effect size (SRM)) were used 
to quantify the strength of CID. RESULTS: CID at 6 months was 5.65 [95% conﬁ-
dence interval: 0.75;10.56] (FAMS TS) and 4.22 [0.02;8.42] (FAMS TOI). All coefﬁ-
cients for “EDSS improved” were signiﬁcantly larger than for “EDSS unchanged” with 
SRM of 0.24 and 0.23, respectively. CONCLUSIONS: CID estimates are provided 
for improvement in HRQOL in patients with MS over a six-month period. The results 
are inline with published CID of FACIT instruments ranging from 4 to 8 units in 
patients with cancer. The estimated CID can assist clinicians and health policy makers 
in evaluating signiﬁcance of short-term treatment effects of medical as well as non-
medical interventions (e.g. patient support programmes).
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OBJECTIVES: To assess the costs and the health-related quality of life (HrQoL) of 
patients with Gilles de la Tourette’s syndrome (GTS) in Germany METHODS: Direct 
and indirect costs as well as HrQoL were evaluated in 200 patients with GTS in three 
outpatient departments in Germany. Economic data was provided in a patient diary 
over a three-months-period. Costs were analyzed from the perspective of the statutory 
health insurance. Indirect costs were calculated by the human capital approach. 
HrQoL was measured using the EuroQol instrument. Depression was assessed using 
the Beck Depression Inventory (BDI) and clinical symptoms with the Yale Tourette 
Syndrome Symptom list (YTSSL) and the Shapiro-Tourette-Syndrome-Severity-Scale 
(STSSS). RESULTS: Direct costs amounted to a635 during the evaluation period. 
Indirect costs totalled to a2500. Major cost components were: drug costs (a350) and 
in-stays (a300). Patients with GTS proved to have a worse HrQoL than a representa-
tive sample of the general German population. In GTS patients the most affected 
EQ-5D domains were anxiety/depression (57.1%), pain/discomfort (47.5%), and daily 
activities (38.4%). The mean EQ VAS score was 65.4 o 21.9. The patients had a mean 
BDI score of 12.3 o 9.9, which was considerably worse compared to a representative 
German sample with a mean BDI score of 6.45 o 5.2. The mean STSSS value was 
3.24 o 1.1. There was no signiﬁcant difference between genders with respect to tic 
severity. A signiﬁcant correlation for BDI, age, YTSSL, STSSS, subjective efﬁcacy of 
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drug treatment, occupational advancement, current work status, and direct cost was 
detected in univariate analyses. CONCLUSIONS: To our best knowledge this is the 
ﬁrst observational study on the burden of GTS in Germany. With annual total costs 
of about a12,500, GTS places a notable ﬁnancial burden on society. HrQoL is 
 considerably reduced in patients with GTS. While tic treatment is important, co-
 morbidities such as depression should be regarded more seriously.
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OBJECTIVES: To assess change in health-related quality of life (HRQoL) over time 
in MS patients treated with natalizumab in a “usual care setting” in the United States 
(US). METHODS: MS patients starting natalizumab were invited to participate in a 
1-year longitudinal health outcomes study assessing their experiences with natali-
zumab. MS patients complete self-reported assessments prior to natalizumab initiation 
and after the 3rd, 6th and 12th natalizumab infusions. The current analysis reports the 
change in general HRQoL assessments using the SF-12v2 from baseline through the 
6th natalizumab infusion. Physical and Mental Component Summary (PCS and MCS, 
respectively) scores were computed at each assessment. PCS and MCS scores range 
from 0 to 100, with higher scores indicating better HRQoL. The a-priori study 
hypothesis was that patient-reported HRQoL improves over time with longer duration 
of natalizumab treatment. Statistical regression models were used to evaluate changes 
in HRQoL over time after controlling for the number of natalizumab infusions, age, 
years since MS diagnosis, baseline disease disability and functional status, comorbidity 
burden, and number of drugs used prior to natalizumab. RESULTS: Data for 296 
patients were analyzed. The mean age was 47 / 11 years and the majority of patients 
were female (78%). The mean number of years since MS diagnosis was 11 / 9 years. 
After controlling for covariates, a statistically signiﬁcant increase (improvement) in 
PCS scores (BL 34 / 11, 3rd 36 / 12 and 6th 36 / 11; p  0.0001) and MCS 
scores (BL 43 / 12, 3rd 47 / 11 and 6th 48 / 11; p  0.0001) was observed from 
baseline through the 6th infusion. CONCLUSIONS: Patients reported signiﬁcant 
improvements in both physical and mental aspects of HRQoL over 6 months of treat-
ment, suggesting an improved effect of natalizumab over time. These results document 
the improvement in HRQoL of MS patients receiving natalizumab in the usual care 
setting and are consistent with clinical study ﬁndings.
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OBJECTIVES: Reports from clinical trials suggest that physical activity (PA) can be 
beneﬁcial for multiple sclerosis (MS) patients. However, participation in PA was found 
to be low in MS patients with substantial physical disability. We assessed levels of PA 
and their interaction with depression and health related quality of life (HRQoL) in 
early-stage MS patients. METHODS: The BEGIN study (Betaferon® treatment and 
Exercise data Gathering IN early MS) is an international prospective observational 
study of early-stage MS patients, including clinically isolated syndrome suggestive of 
MS, treated with Betaferon®. PA levels were assessed by the International Physical 
Activity Questionnaire (IPAQ) and a pedometer, and depression using the Center for 
Epidemiological Studies Depression Scale (CES-D), and HRQoL with the EuroQoL 5 
dimension (EQ-5D) utility scale and Visual Analogue Scale (VAS) score. RESULTS: 
PA data were collected from 609 patients (68.0% women) in 16 countries in Europe, 
Asia, Australia and Latin America. Mean age was 36.3 years (SD  9.9). The median 
MET-minutes/week derived from IPAQ at baseline was 3349 (SD  3616), with 
25.2%, 32.5% and 42.6% of patients categorized as low, moderate and high PA level, 
respectively. The median steps per day were 6,728 (IQR  4,942). A negative Spear-
man’s rank correlation was found between the steps per day and depressive symptoms 
(p  0.01).Mean depression scores decreased monotonically in higher IPAQ categories. 
EQ-5D utility and VAS scores were on average 0.7 (SD  0.2) and 71.7 (SD  19.5), 
respectively. The steps per day showed to be positively correlated with both VAS 
(p  0.01) and utility (p  0.01) outcomes. CONCLUSIONS: PA in early-stage MS 
patients was found to be positively associated with HRQoL. Adding the results of the 
longitudinal data after two years of follow-up may lead to further insights regarding 
the role of PA in early-stage MS patients and its relation to HRQoL.
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OBJECTIVES: To assess patient-reported treatment satisfaction with natalizumab in 
MS patients in the United States (US). METHODS: MS patients initiating natalizumab 
were invited to participate in a longitudinal study. Patients complete self-reported 
assessments prior to natalizumab initiation and then after the 3rd, 6th and 12th natali-
zumab infusions. As part of the baseline (BL) assessment, patients reported their sat-
isfaction with MS drugs used prior to natalizumab initiation. For the follow-up 
assessments, patients reported their satisfaction with natalizumab treatment. Patient 
self-reported measures included satisfaction with treatment effectiveness, convenience 
of use, and global treatment satisfaction scales from the Treatment Satisfaction Ques-
tionnaire. Each scale consists of 3 items, with responses measured on a 7-point Likert 
Scale ranging from 1 (low) to 7 (high). Individual item responses are added and scores 
are transformed to a 0 to 100 scale with higher scores indicating higher satisfaction. 
This analysis evaluates the change in satisfaction from baseline through the 6th natali-
zumab infusion after controlling for number of natalizumab infusions, age, years since 
MS diagnosis, baseline disease disability and functional status, comorbidity burden, 
and number of MS drugs used prior to natalizumab. RESULTS: Data from 296 
patients indicated that 78% are female, the mean age is 47 o 11 years and the mean 
time since MS diagnosis is 11 o 9 years. Almost all (97%) patients used at least one 
other MS drug before natalizumab. After controlling for covariates, signiﬁcant 
increases in effectiveness (BL 44.22 o 8.62, 3rd 61.91 o 6.87 and 6th 69.48 o 4.96, p 
 0.0001), convenience (BL 60.80 o 6.27, 3rd 79.18 o 3.25 and 6th 79.69 o 0.42, p  
0.0001), and global satisfaction (BL 62.46 o 3.92, 3rd 75.36 o 3.92 and 6th 76.51 o 
3.92, p  0.0001) were observed. CONCLUSIONS: Patients’ satisfaction with natali-
zumab increased with increasing treatment duration. Patients reported higher levels 
of satisfaction with treatment effectiveness, convenience of use, and global satisfaction 
while receiving natalizumab compared to their satisfaction levels with MS drugs 
received before initiating natalizumab.
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OBJECTIVES: Estimating the minimal important difference (MID) of patient reported 
outcome (PRO) measures is important to guide interpretations of scores and for 
assessing treatment efﬁcacy in clinical trials and studies. The current study was 
designed to estimate the MID of newly developed PROs for Multiple Sclerosis (MS); 
The Patient Reported Indices for Multiple Sclerosis (PRIMUS; which includes Activity 
and Quality of Life (QoL) scales) and Unidimensional Fatigue Impact Scale (U-FIS). 
The measures have been shown previously to be unidimensional, valid and reliable. 
METHODS: Data were taken from the TRANSFORMS study, a multi-country phase 
III study evaluating the safety and efﬁcacy of oral ﬁngolimod compared to IFNB-1a 
i.m. in relapsing-remitting MS patients. PRO assessments were completed at baseline, 
6 and 12 months. Measures included the PRIMUS-Activities (scored 0–30), PRIMUS-
QoL (scored 0–22), U-FIS (scored 0–66) and EQ-5D. For PRIMUS and U-FIS scales, 
a high score indicates more severe impact. Both anchor (published EQ-5D MID values) 
and distribution (0.2 and 0.5 effect sizes, standard error of measurement) based 
approaches were employed. Anchor-based MID values were assessed both for indi-
viduals who improved or deteriorated according to EQ-5D MID values. Triangulation 
of results provided the ﬁnal PRIMUS and U-FIS MID estimates. RESULTS: Trial 
sample: n  1292, 67.3% female, mean age 36.2 (SD  8.5), mean MS duration 7.4 
years (SD  6.2). Anchor and distribution based MID’s ranged from 0.9–2.9 (PRIMUS 
QoL), 0.7–2.3 (PRIMUS Activities) and 2.4–7.3 (U-FIS). Triangulation resulted in the 
following MID values; PRIMUS Activities 1.5 for individuals improving or deteriorat-
ing; PRIMUS QoL 1.5 for individuals improving or deteriorating and U-FIS 4.5 for 
those improving and 5.0 for those deteriorating. CONCLUSIONS: The analyses 
provide preliminary information on the interpretation of scores on the scales. The 
MID values will aid the assessment of treatment efﬁcacy in clinical trials and 
studies.
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OBJECTIVES: To measure the association of health-related quality of life (HRQoL) 
and pre-baseline relapse among multiple sclerosis (MS) patients in a real-world obser-
vational study. METHODS: The Real-World Betaseron Outcomes Study (ROBUST) 
is a 12-month, US prospective, observational, open-label, single-arm, multi-center 
outcomes study of interferon beta-1b given every other day for MS. Patient outcomes, 
including relapse history, were reported independently by both patients and physicians 
via a web-based data capture tool. A total of 226 patients were registered across 52 
sites, and 193 completed the baseline survey. Analysis of variance methods were used 
to measure the association of SF-12 Health Survey (SF-12) scores and pre-baseline 
relapse descriptors (relapse status, frequency, severity of typical and worst relapse). 
SF-12 results were summarized by Physical Component Score (PCS-12) and Mental 
Component Score (MCS-12). RESULTS: Both physical and mental scores were lower 
among patients reporting to be in relapse at baseline (N  78) than among those 
reporting to be relapse-free at baseline (N  115); however, the difference was statisti-
cally signiﬁcant only on the MCS-12 (43.9 vs. 40.5; p  0.045). Reduction of both 
PCS-12 and MCS-12 were strongly associated with increasing frequency of patient 
